{
  "docId": "019de073-187a-71e9-a3c0-2f4159454068",
  "docSlug": "48ce63a07f3c546c39a71c96ea43409e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 40,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": "The slide uses a three-column layout to categorize performance metrics and clinical pipeline updates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-187a-71e9-a3c0-2f4159454068/5",
  "deckHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068",
  "deckJsonHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068.json",
  "deckAnchorHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.85
      },
      "kind": "callout",
      "text": "2022 guidance: low twenties % Total Revenue growth (CER) (updated) | mid-to-high twenties % Core EPS growth (CER)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1dad193c-e330-4748-8627-20a6cb7cabf0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for year-to-date (YTD) June 2022, unless stated otherwise.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b8a0a4f-a80b-43e0-adf9-53f7c63aa5ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "list",
      "text": "Broad-based performance: Oncology $7.5bn (+22%), BioPharmaceuticals $10.4bn (+31%), Rare Disease $3.5bn (+10%)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82e56c22-0fed-43c0-af6b-09c511d8993e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "Robust growth: Total Revenue $22.2bn (+48%), Core EPS $3.61 (+44%), Increasing 2022 Total Revenue guidance at CER, Increased interim dividend to $0.93",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd923f01-80eb-4d8c-bbea-5b71b68a70fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.68,
        "y": 0.25
      },
      "kind": "list",
      "text": "Science-led innovation: Farxiga, Ultomiris, Imfinzi, Enhertu, Tezspire, Lynparza developments",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f68738af-7318-4f99-8682-5f9858b0971c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "H1 2022: key updates",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "833068d1-2bd2-481c-aa53-cfb69aa59c65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "title",
      "text": "Progress against our strategic objectives",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "909dbc1a-1f15-4e8d-b3d8-64573e122c83",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "dad6321f-940c-4592-93ff-d62d98a7139b",
      "evidence": "list/bullet: Robust growth: Total Revenue $22.2bn (+48%), Core EPS $3.61 (+44%), Increasing 2022 Total Revenue guidance at CER, Increased interim dividend to $0.93",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}